The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.00 (0.00%)
Spread: 0.70 (7.955%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.15
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Image Scan sinks as it expects to post significant loss in first half

Tue, 22nd Feb 2022 11:50

(Alliance News) - Image Scan Holdings PLC shares tanked on Tuesday after the company said it expects to post a significant loss for the first half of financial 2022 and thinks it is "unlikely" that the second half will fully recover the loss.

Shares were down 34% at 1.99 pence each on Tuesday around midday in London.

The Leicestershire, England-based imaging systems provider said sales of its industrial scanners continue to be hit by disruption in the automotive industry. It noted that both customer demand and global supply chains in the industry have been negatively impacted by Covid-19.

In the first half of financial 2022, ending March 31, Image Scan said the pandemic hit customer spending ,as well as the operation of its sales and service functions.

As a result, orders were delayed, causing the "momentum that build up in the second half of financial 2021 to stall". The company now expects to make a "significant" loss in the first half of financial 2022.

Although, Image Scan expects full-year results to be weighted to the second half, due to a "strong" pipeline of orders across the world, the "timing of those orders is hard to predict in the current environment."

Image Scan, therefore, said it believes that it is "unlikely that the second half will be sufficiently strong to enable the Company to fully recover the first half loss."

In financial 2021, Image Scan generated revenue of GBP2.9 million and a pretax profit of GBP188,824.

"It is disappointing that our order intake has stalled in the first half of the year. While international travel for trade shows and demonstrations is still limited, we have a healthy pipeline of new business," Chair & Chief Executive Bill Mawer said.

"However, it will take some time for that business to come through. Together with the loss of Covid-19 government support mechanisms, this gives us less confidence in our original expectation for the current financial year. The positive response to the launch of our new products gives us confidence for the longer term but, in the continuing, challenging environment, it has to be expected that it will take a while for order levels to recover."

More positively, the company noted that it launched its ThreatScan-AS1 fully integrated portable X-ray system and a new high energy, X-ray generator.

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Nov 2019 10:01

Scancell To Receive New European Patent For Moditope Product

Scancell To Receive New European Patent For Moditope Product

Read more
23 Oct 2019 10:48

Scancell Hires Former Genkyotex Boss Ursula Ney As Non-Executive

Scancell Hires Former Genkyotex Boss Ursula Ney As Non-Executive

Read more
5 Sep 2019 16:03

UK Shareholder Meetings Calendar - Next 7 Days

Friday 6 SeptemberMySale Group (re share placing)Berkeley GroupGreene 9 African Oil & 10 11 Design

Read more
4 Sep 2019 08:58

Scancell signs collaboration agreement with antibody technology company

(Sharecast News) - Cancer treatment developer Scancell has inked its first collaboration agreement with a "leading" antibody technology company for its new platform technology, AvidiMab.

Read more
20 Aug 2019 10:59

Scancell losses deepen as it presses on with development

(Sharecast News) - Novel immunotherapies developer Scancell Holdings reported a deeper operating loss in its final results on Tuesday, to £6.73m compared to £4.91m in the 2018 financial year.

Read more
20 Aug 2019 10:59

Scancell Annual Loss Widens Amid Product Pipeline Development

(Alliance News) - Immunotherapy firm Scancell Holdings PLC on Tuesday said its loss widened on higher development costs, while it is making strong progress on advancing its the 12 months to the of

Read more
19 Aug 2019 09:33

Scancell to begin SCIB1 UK trial as FDA issues linger in US

(Sharecast News) - Immunotherapy developer Scancell announced the initiation of and further updates to the 'SCIB1' phase 2 trial in patients with metastatic melanoma also receiving the checkpoint inhibitor 'pembrolizumab' (Keytruda) on Monday.

Read more
13 Aug 2019 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 14 August AvastHalf Year ResultsLookersHalf Year BeattyHalf Year Year

Read more
1 Jul 2019 14:42

Scancell Progresses Trials In "Busy And Productive" Six Months

(Alliance News) - Scancell Holdings PLC said on Monday it has been a "busy and productive" six months for the company.The company said that active patient recruitment for the two

Read more
18 Jun 2019 14:40

Scancell Appoints Vulpes Investment Management Co-Founder To Board

(Alliance News) - Scancell Holdings PLC on Tuesday said it has appointed Vulpes Investment Management Co-Founder & Portfolio Manager Martin Diggle to its board.Diggle joins the cancer a

Read more
13 Jun 2019 13:48

Scancell Shares Jump 30% As Vulpes Invests GBP4 Million (ALLISS)

(Alliance News) - Scancell Holdings PLC's shares soared Thursday as it received GBP3.9 million from a new investor.Scancell shares were up 31% in afternoon trade at a price of 7.00 Life

Read more
21 May 2019 13:25

N4 Pharma Appoints John Chiplin as Non-Executive Chairman

LONDON (Alliance News) - N4 Pharma PLC on Tuesday said it appointed John Chiplin as non-executive chair of the company with immediate effect.Furthermore, the pharmaceutical firm appointed a

Read more
20 May 2019 11:03

Scancell partnership with Cancer Research moves closer to clinic

(Sharecast News) - Immunotherapy developer Scancell Holdings updated the market on its clinical development partnership with Cancer Research UK for the development of the ;ImmunoBody' vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer (NSCLC), on Monday.

Read more
20 May 2019 11:02

Scancell Says Cancer Vaccine SCIB2 Will Be Given Using New Formulation

LONDON (Alliance News) - Scancell Holdings PLC said Monday cancer vaccine SCIB2 is to be administered using a new nanoparticle formulation in an early stage trial.Shares in Scancell were up

Read more
10 May 2019 10:49

Scancell Creates Advisory Board And Prepares For Drug Trials

LONDON (Alliance News) - Scancell Holdings PLC on Friday said it has established a clinical advisory board and has begun manufacturing and toxicity testing on its tumour drug in immunotherapy were

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.